Forecast

The analysts' average price target is +16,02€ (+17,02%). The median is +16,30€ (+19,07%).

Buy	11
Hold	3
Sell	1

News Go to news feed

Replimune Group reaches 52-week high after FDA approval of Tudriqev

Replimune Group’s stock rose to a 52-week high of $15.72 and is currently trading at $15.69, implying a market capitalization of about $1.47 billion. Over the past year the share gained 174.3%, while InvestingPro warns the stock may currently be trading above its fair value. Options data suggest a potential price move of roughly 5.6% ahead of the quarterly results. Several analysts (Wedbush, Leerink, Cantor Fitzgerald) raised their valuations following the FDA approval of Tudriqev and positive prospects for RP-1 in combination with nivolumab. » More on de.investing.com
Replimune Group: options market signals 5.6% price move ahead of quarterly results

The options market implies an expected 5.6% price move for Replimune Group around the quarterly results expected on August 21; the exact publication date has not yet been confirmed. Historical comparisons show that actual stock reactions to previous quarterly reports sometimes differed markedly from the implied moves, with both larger gains and sizable declines. » More on de.investing.com
Replimune rises after FDA approval for TUDRIQEV and $150 million capital raise

Replimune shares climbed intraday by 15.3% to $13.90, reaching a new 52-week high. On August 6 the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab for the treatment of advanced, unresectable cutaneous melanoma after prior anti‑PD‑1 therapy. At the same time the company placed a guaranteed $150 million capital increase (price $12.06/share) with expected net proceeds of about $140.5 million to bolster the balance sheet for the commercial launch; analysts raised price targets and valuations. Management now faces the task of showing a credible path from approval to revenue generation while investors price in the anticipated commercial opportunities for TUDRIQEV. » More on de.investing.com

Financials

In the last quarter, Replimune Group had revenue of 0.00€ and net profit of −61.13m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	−61.13m	16,89%
EBITDA	−57.85m	23,75%

Fundamentals

Metric	Value
Market capitalization	+1.14b€
Number of shares	84.03m
52-week high/low	+13,64€ - +1,29€
Dividends	No
Beta	0,9
P/E ratio	−5,02
PEG ratio	−0,83
P/B ratio	+14,49
P/S ratio	0,00

Company profile

Die Replimune Group, Inc. ist ein Biotechnologieunternehmen, das onkolytische Immuno-Gentherapien zur Behandlung von Krebs entwickelt. Es nutzt seine firmeneigene Immuntherapie-Plattform, um Produktkandidaten zu entwerfen und zu entwickeln, die das Immunsystem gegen Krebs aktivieren sollen. Der führende Produktkandidat des Unternehmens ist RP1, eine selektiv replizierende Version des Herpes-Simplex-Virus 1, die sich in klinischen Studien der Phase I/II für eine Reihe von soliden Tumoren und in klinischen Studien der Phase II für Patienten mit Plattenepithelkarzinomen der Haut befindet. Darüber hinaus entwickelt das Unternehmen RP2, das sich in der klinischen Phase I für ein Anti-CTLA-4-Antikörper-ähnliches Protein befindet, um die Hemmung der Immunantwort zu blockieren, die ansonsten durch CTLA-4 verursacht wird, sowie RP3, das sich in der klinischen Phase I befindet, um immunaktivierende Proteine zu exprimieren, die T-Zellen stimulieren. Die Replimune Group, Inc. wurde 2015 gegründet und hat ihren Hauptsitz in Woburn, Massachusetts.